Ji Research Group In The Division of Oncology

Projects

Our research group is focused on developing "personalized" medicine strategies for improving the clinical management, prevention and treatment of individuals with cancer or at high risk of developing cancer. Personalizing the care of individuals with or at high risk for cancer requires identifying the spectrum of critical cancer mutations and genomic aberrations which are responsible for any individual cancer's development and phenotype. New genomic technologies involving next generation sequencers (NGS) have opened the way for creating personalized genetic signatures which can be used to tailor the clinical management of individuals with cancer. This involves the analysis of cancer genome DNA sequences.

To accomplish this goal, our research group is developing accessible, rapid and highly cost-effective methods of "clinical" DNA sequencing" of cancer and human genomes for discovery and diagnostic validation. These approaches have the potentially to accelerate the application of clinical discoveries with diagnostic potential. Our ongoing projects include:

  1. Primarily genomic sequencing technology development
  2. Novel computational approaches towards analyzing cancer and human genomes
  3. Investigation of populations of individuals with cancer
  4. Genetic analysis of mystery families with a history of cancer

More specifically, we are investigating the clinical impact of mutations and other genomic errors associated with the gastrointestinal cancer genome that influence cancer prognosis and affect key signaling pathways that are critical in tailoring the optimal therapy for any individual. Secondly, we are using human genome sequencing approaches to identify mutations which increase the risk of cancer in mystery families which have eluded classification via traditional clinical genetic diagnostics.

While our focus is primarily on gastrointestinal cancer, our approaches have wide applicability to all cancers and will enable the discovery of diagnostics which will clarify the key clinical questions of patient management and potentially lead to new personalized treatment strategies.

Footer Links: